RespireRx Pharmaceuticals Inc. Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update

GLEN ROCK, NJ--(Marketwired - Aug 25, 2017) -  RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for the treatment of neurologically controlled respiratory disorders, including obstructive sleep apnea and opioid induced respiratory depression (a form of central apnea) and other respiratory and neurological conditions, has filed its June 30, 2017 Quarterly Report on Form 10-Q and is hereby providing an update on the Company's operating and financing activities and its plans for the remainder of 2017.

Comments by Chief Executive Officer

James S. Manuso, Ph.D., President, Chief Executive Officer and Vice Chairman of RespireRx, commented, "We are pleased to report that RespireRx has retained a leading advisory firm to assist in the Company's advancement of its objective to engage a partner for the further development into Phase 3 clinical trials of dronabinol for obstructive sleep apnea and of ampakines into Phase 2B clinical trials for the treatment of opioid-induced respiratory depression, a form of central apnea and other neurally mediated respiratory disorders. We look forward to reporting on our progress with respect to this initiative in the months ahead. Naturally, we continue to seek to raise additional capital to fund our operations and we are continuing our efforts to strengthen our balance sheet."

Corporate Overview

Key corporate developments during the three months ended June 30, 2017 included the following:

• On June 6, 2017 at the Sleep 2017 conference in Boston, MA, a podium presentation by the principal investigator described the breakthrough results, previously announced by the Company, of a Phase 2B study in which oral administration of dronabinol improved the symptoms of obstructive sleep apnea. 
  
  
• Also at the Sleep 2017 conference, Senior Vice President of Research and Development, Richard Purcell presented a poster ("Poster") session entitled: "OPIOIDS AND SLEEP APNEA: ANTAGONISM OF REMIFENTANIL INDUCED RESPIRATORY DEPRESSION BY CX1739 IN TWO CLINICAL MODELS OF OPIOID INDUCED RESPIRATORY DEPRESSION." SLEEP 2017 was the 31st Annual Meeting of the Associated Professional Sleep Societies LLC ("APSS"), a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society.